glp-1 obesity drugs pipeline Market Overview: Agonists and the Market | Blog Solving the Unmet Needs in

However, not all tested GLP-1RAs have consistently demonstrated reductions in cardiovascular events, and the impact on specific cardiovascular outcomes varied among the effective drugs

Recent clinical trials demonstrated that SGLT2 inhibitors and GLP-1RAs bring beneficial effects on the cardiorenal outcomes of T2D subjects who are at high risk for CVD

If the medication is stopped, weight regain and rising blood sugar can occur, as shown in clinical studies

This side effect has not been reported at similar rates with semaglutide or tirzepatide and appears to be related to the glucagon receptor activation component unique to retatrutide

Obesity, primarily associated with the increased burden of non-communicable diseases (NCDs), has been linked to healthcare costs approximately 30% higher than those of individuals with normal body weight [9]